Monozygotic Twins with MAGT1 Deficiency and Epstein–Barr virus-positive Classic Hodgkin Lymphoma Receiving anti-CD30 CAR T-cell Immunotherapy: A case Report

Epstein-Barr virus (EBV)-positive classical Hodgkin lymphoma (cHL) is the most common malignancy in patients with “X-linked immunodeficiency with magnesium defect, EBV infection, and neoplasia” (XMEN). Aberrant expression of MAGT1 leads to XMEN, a congenital disorder of combined primary immunodeficiency (PID) characterized by increased susceptibility to chronic EBV infection and EBV-associated lymphoproliferation [1]. Patients with variants in MAGT1 suffer from an N-linked glycosylation defect, resulting in low CD4⁺ cell counts with an inverted CD4:CD8 ratio, reduced expression of NKG2D (a natural killer (NK)-cell activating receptor) on NK cells and cytotoxic T lymphocytes (CTLs), and impaired T-cell activation through NKG2D [2].

A variety of approaches have been used to control this disease. However, the therapeutic effects are limited [3]. A new approach involving chimeric antigen receptor (CAR) T cells specific for CD30 can be used to treat relapsed or refractory (r/r) HL. Previously, we reported the safety, efficacy and robust long-term performance of CD30 CAR T-cell immunotherapy in our center [4]. However, there have been no reports on CAR T-cell therapy for lymphoma in XMEN thus far. Here, we present the first case of an identical twin with MAGT1-deficient cHL receiving murine CD30 CAR T-cell therapy and hope to provide insight into a therapeutic strategy for such patients.

The twins were referred to our hospital to receive murine anti-CD30 CAR T cell therapy. Before treatment, CD30 target antigen expression was confirmed by immunohistochemical staining of the initially diagnosed lymph nodes (Supplemental Fig. 1). The structure (Fig. 1A) and manufacturing of CAR T cells are described in the Supplemental Methods as previously described [4]. The twins were given a standard dose of the FC regimen on days − 5 to -3 as lymphodepletion. Anti-CD30 CAR T cells (4 × 10⁶ kg/day) were infused on days 0–3 and days 0–5 for twins 1 and 2, respectively (Fig. 1B). T cells with the anti-CD30 CAR transgene expanded and persisted well in the twins compared with the previously reported average level in our center [4]. The key factors related to the therapeutic effect of CAR-T cells are presented in Supplemental Table 2. Compared to those of twin 2, twin 1 had a higher level of CAR T-cell expansion and longer persistence (Fig. 1C and D, Supplemental Table 3), and the level of interleukin-6 (IL-6) was greater in twin 1 (Fig. 1E). Grade 1 and grade 0 cytokine release syndrome (CRS) were observed in twin 1 and twin 2, respectively (Fig. 1F). Neither of the twins experienced any significant infections or neurological symptoms before or after CAR-T cell therapy. The twins achieved complete remission (CR) at + 3 months after CAR T-cell infusion. Twenty-three months later, twin 1 developed PD, but twin 2 remained in CR (Fig. 1G). Then, twins 1 and 2 received 200 mg of anti-PD-1 antibody every 1–2 months and every 2 months, respectively. As of December 2023, Twin-1 was maintained in stable disease (SD), and Twin-2 remained in CR.

In contrast, the twins’ half-brother, who shares the same mother and is 10 years older, currently remain healthy. The patients did not have a family history of cancer. To explore potential inborn errors of immunity (IEIs) underlying the persistent refractoriness of these young twins, whole-genome sequencing (WGS) was retrospectively performed on the peripheral blood mononuclear cells (PBMCs) of the twins and their older half-brother. WGS data have been uploaded to the National Center for Biotechnology Information (NCBI): PRJNA809536. The 2022 Immunological Societies Expert Committee (IUIS) updated gene list was included in the analysis. The filtered nonsynonymous variants are showed in Supplemental Table 4. Alterations that the twins shared but the half-brother lacked were selected. Among these, a complex hemizygous frameshift variant in MAGT1 (c.131_134delinsGTGGTGGTTTTGGTGTGT, p.Val44Glyfs*38, NM_032121.5), which has never been reported in public databases (1000G, ExAC, and GenomAD), was identified (Fig. 1J). Sanger sequencing confirmed that the twins were hemizygous for the MAGT1 frameshift variant, while their half-brother and mother carried the wild-type gene (Fig. 1H, I). In addition, XMEN-related clinical manifestations and laboratory findings of the twins were identified [1] and shown in Supplemental Fig. 2A-3 H.

Furthermore, several functional experiments in vitro were performed to explore the characteristics of XMEN. As the CAR30 transgene was detected at zero copy number by droplet digital polymerase chain reaction (ddPCR) in both twins, there was no impact on the activity of CAR T-cells in vitro. First, NKG2D, the best biomarker of XMEN disease, was assessed, and it was found to be decreased in both CD8⁺ T cells and NK cells from twins compared those from mothers and two healthy donors (Fig. 1K, Supplemental Fig. 3). Second, the twins’ CD8⁺ T cells and NK cells had impaired expression of perforin (Fig. 1L, Supplemental Fig. 4) and diminished cytotoxicity when stimulated (Fig. 1M). Third, degranulation assays indicated that activated CTLs and NK cells were normal, while resting CTLs and NK cells were deficient (Fig. 1N, Supplemental Fig. 5).

XMEN is caused by loss-of-function variants in MAGT1. In the present case, identical twins suffered from the same type of disease due to the same MAGT1 hemizygous deletion. In addition, next-generation sequencing (NGS) revealed typical genetic aberrations (Supplemental Table 4) in cHL according to the initial diagnosis via formalin-fixed, paraffin-embedded (FFPE) sequencing, indicating that germline MAGT1 alteration was the pathogenic driving factor [5].

In the present patients, MAGT1 germline mutation screening was not performed during diagnosis or at the beginning of CAR T-cell therapy. Our case underscores the importance of identifying MAGT1 deficiency in young patients with EBV-positive lymphoproliferative disease through high-throughput sequencing.

There is no international consensus on the treatment of XMEN. Anti-CD20 therapy with rituximab for EBV control has not been recommended because of its inconsistent efficacy and lack of effect on chronic EBV infection [1]. Magnesium supplementation therapy has been proven ineffective in a clinical trial (US National Institutes of Health ClinicalTrials.gov#NCT02496676). HSCT has also been attempted in some patients, but posttransplant mortality remains high [3]. Recently, Brault et al. presented data on a novel gene-editing approach that utilizes CRISPR-Cas9 to compensate for the deletion of the MAGT1 gene [6]. Despite this exciting progress, there is still a long way to go for clinical applications of this new technique.

Although allo-HSCT can be curative for immunodeficient patients, most XMEN patients die from transplant-related complications [3]. The decision for allo-HSCT in patients with XMEN, should be balanced against the risks and the availability of a suitable donor. In this case, we recommended that Twin-1 received allo-HSCT from an unrelated healthy donor as a salvage approach when the disease progressed after CAR T-cell therapy. However, his parents repeatedly declined HSCT and requested that he take anti-PD-1 antibodies for maintenance.

In conclusion, if lymphoma is diagnosed at a young age or has a poor therapeutic outcome, it should be suspected to be a possible IEI. A novel inherited germline alteration in MAGT1 was identified, and this case is the first time CAR T-cell immunotherapy has been used in XMEN. CD30 CAR T-cell therapy may be a viable option for XMEN patients with r/r HL. More prospective experimental data are needed to explore the potential of bridging HSCT with CAR T-cell therapy.